Elbit Systems Ltd. (NASDAQ:ESLT) belongs to Industrial Goods sector. Its net profit margin is 5.80% and weekly performance is 4.46%. On last trading day company shares ended up $78.24. Elbit Systems Ltd. (NASDAQ:ESLT) distance from 50-day simple moving average (SMA50) is 1.73%. On June 12, Elbit Systems of America, LLC, a wholly owned subsidiary of Elbit Systems Ltd. (NASDAQ:ESLT) announce that it has been selected by the Shanghai Avionics Corporation (SAVIC) to provide the Kollsman Enhanced Vision System-Superior Performance (EVS-SP™) for the COMAC C919 aircraft. Elbit Systems of America, working with official sales representative, East Wonder, Inc. secured the contract with SAVIC which enables future operators of the C919 to select the EVS-SP through the aircraft manufacturer.
CTI BioPharma Corp. (NASDAQ:CTIC) shares decreased -2.39% in last trading session and ended the day at $2.04. CTIC Gross Margin is 98.50% and its return on assets is -136.90%. CTI BioPharma Corp. (NASDAQ:CTIC) quarterly performance is 3.55%. On June 12, CTI BioPharma Corp. (NASDAQ:CTIC) and Baxter International’s BioScience business (BAX) announced new patient-reported outcome (PRO) data for pacritinib – an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3 – from the Phase 3 PERSIST-1 study. As recently reported at the American Society of Clinical Oncology (ASCO) annual meeting, results show a significant reduction in the Total Symptom Score (TSS) (the proportion of patients with a 50 percent or greater reduction in TSS from baseline to Week 24), and in each individual common disease-related symptom, from baseline to Week 24, in patients treated with pacritinib compared to best available therapy (exclusive of a JAK inhibitor) (BAT).
On 12 June, AbbVie Inc. (NYSE:ABBV) shares decreased -1.46% and was closed at $67.05. ABBV EPS growth in last 5 year was -17.80%. AbbVie Inc. (NYSE:ABBV) year to date (YTD) performance is 4.09%. Galapagos NV (NASDAQ:GLPG) announced a joint presentation with AbbVie (NYSE:ABBV) at the 38th annual European Cystic Fibrosis Society conference in Brussels, Belgium. Galapagos and AbbVie are working together to develop a triple combination therapy for cystic fibrosis patients with the Class II (F508del) mutation. Novel potentiator GLPG1837 is currently in Phase 1 and is expected to enter a Phase 2 study in class III mutation patients before end 2015. Novel corrector GLPG2222 is expected to enter Phase 1 before end 2015.
Autohome Inc. (NYSE:ATHM) ended the last trading day at $48.43. Company weekly volatility is calculated as 4.45% and price to cash ratio as 12.04. Autohome Inc. (NYSE:ATHM) showed a weekly performance of 4.51%. On June 12, Autohome Inc. (NYSE:ATHM) announced that Mr. Xiang Li will step down from the position of President of the Company while remaining as a director on the board of directors, effective immediately.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ended the last trading day at $110.13. Company weekly volatility is calculated as 5.84% and price to cash ratio as 11.91. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) showed a weekly performance of -10.19%. Forty percent of patients, most with a particularly aggressive form of leukemia, responded to an experimental Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) drug, including several who experienced complete remission, according to data presented on Friday.